All AbMole products are for research use only, cannot be used for human consumption.
MSA-2 is an orally available non-nucleotide STING agonist with antitumor activity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models. MSA-2 dosed via either PO or SC regimens achieved comparable exposure in both tumor and plasma. MSA-2 also exhibits dose-dependent antitumor activity when administered by IT, SC, or PO routes, and dosing regimens were identified that induced complete tumor regressions in 80 to 100% of treated animals. In tumor models that are moderately or poorly responsive to PD-1 blockade, combinations of MSA-2 and anti-PD-1 antibody are superior in inhibiting tumor growth and prolonging survival over monotherapy.
Cancer Lett. 2023 Oct 1;573:216370.
Low-dose metronomic chemotherapy triggers oxidized mtDNA sensing inside tumor cells to potentiate CD8+ T anti-tumor immunity
MSA-2 purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | THP-1 cells, mouse macrophages |
| Preparation method | In the primary screen, THP-1 cells are incubated, in 1536-well plates, with test compounds (20 μM) in a RPMI1640-based assay medium in the presence of 5% carbon dioxide at 37°C for 5 hours. IFN-b levels are determined using an AlphaLISA assay and an EnVision Reader and expressed as percentages of IFN-b induced by cGAMP. STING binding activity of compounds is evaluated with a competitive radioligand binding assay using tritiated cGAMP and membrane embedded full-length recombinant human and mouse STING generated in insect cells. STING pathway activation by MSA-2 is assessed by Western blotting, probing phosphorylation status and total protein levels of STING, TBK-1, and IRF3 by using commercially available antibodies. |
| Concentrations | 20 μM, 0.16 μM-100 μM |
| Incubation time | 5 h |
| Animal Experiment | |
|---|---|
| Animal models | C57BL/6J mice, NSG mice, BALB/c mice, nude NCr mice |
| Formulation | - |
| Dosages | 25 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, 80 mg/kg, 160 mg/kg |
| Administration | intra tumor injection, SC, PO |
| Molecular Weight | 294.32 |
| Formula | C14H14O5S |
| CAS Number | 129425-81-6 |
| Solubility (25°C) | DMSO ≥ 40 mg/mL |
| Storage | 2-8°C, protect from light, sealed |
| Related STING Products |
|---|
| Vadimezan
Vadimezan (DMXAA; ASA-404) acts as a tumor vascular disrupting agent (tumor-VDA), is also a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. |
| G10
G10 is a activator of STING-dependent signaling. |
| 3′3′-cGAMP
3',3'-cGAMP is an endogenous second messenger in metazoans and triggers interferon production in response to cytosolic DNA. 3',3'-cGAMP activates stimulator of interferon genes (STING), which activates a signaling cascade leading to the production of type I interferons and other immune mediators. |
| diABZI (tautomerism)
diABZI (STING agonist 1; Tautomerism) is a selective stimulator of interferon genes (STING) receptor agonist, with EC50s of 130, 186 nM for human and mouse, respectively. |
| C-176
C-176 is a potent, selective and blood-brain barrier permeable inhibitor of STING. C-176 covalently targets transmembrane cysteine residue 91 and thereby blocking activation-induced palmitoylation of STING. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
